Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer

Published:2021-01-18 Issue:2 Volume:64 Page:925-937
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Meng Yonggang¹,Yu Bin²,Huang He¹,Peng Youmei³,Li Ertong¹,Yao Yongfang²,Song Chuanjun¹^ORCID,Yu Wenquan¹^ORCID,Zhu Kaikai⁴,Wang Kai⁴,Yi Dongxu⁴,Du Jinfa⁵,Chang Junbiao¹⁶^ORCID

Affiliation:

1. College of Chemistry, Zhengzhou University, Zhengzhou 450001, China

2. School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

3. Henan Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China

4. Henan Metab Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China

5. Henan Genuine Biotech Co., Ltd. 10 Fuxing Road, Xincheng District, Pingdingshan, Henan 467036, China

6. Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China

Funder

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c02005

Reference43 articles.

1. Epidermal growth factor receptor mutations in lung cancer

2. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

3. The epidermal growth factor receptor family: Biology driving targeted therapeutics